Depression is among the most prevalent, devastating, and undertreated disorders in our society. Treatment with antidepressant medications is effective in controlling symptoms, but treatment beyond the point of symptom resolution is necessary to restore functional status and prevent recurrent episodes. An important step in improving compliance is to identify the determinants of antidepressant treatment compliance. A broader motivation for our study is to examine compliance by patients with a chronic but treatable disease. With claims data between 1990 and 1993, this study uses logistic regression analysis to examine the determinants of compliance among 2,012 antidepressant recipients. The results show that initiating treatment with a tricyclic antidepressant reduces the probability of antidepressant treatment compliance. Initiating treatment with a selective serotonin reuptake inhibitor and undergoing family, group, or individual psychotherapy treatments increase the probability of compliance. Case management does not meaningfully affect compliance. Implications for policy and clinical practice are discussed.
Get full access to this article
View all access options for this article.
References
1.
Agency for Health Care Policy and Research . 1999. Treatment of depression—newer pharmacotherapies: Summary, evidence report/technology assessment: Number 7. AHCPR Pub. No. 99-E013. Rockville, MD: Author.
2.
American Psychiatric Association . 1993. Practice guideline for major depressive disorder in adults. American Journal of Psychiatry150:1-26.
3.
Andersen, R.1995. Revisiting the behavioral model and access to medical care: Does it matter?Journal of Health and Social Behavior36 (1): 1-10.
4.
Anderson, D. , J. Berlant, D. Mauch, and W. Maloney. 1997. Managed behavioral health care services. In Essentials of managed health care, edited by P. Kongstvedt, 2d ed.Gaithersburg, MD: Aspen.
5.
Berndt, E. R. , S. N. Finklestein, P. E. Greenberg, R. H. Howland, A. Keith, A. J. Rush, J. Russel, and M. B. Keller. 1998. Workplace performance effects from chronic depression and its treatment. Journal of Health Economics17:511-535.
6.
Berndt, E. R. , R. Frank, and T. McGuire. 1996. Alternative insurance arrangement and the treatment of depression: What are the facts? National Bureau of Economic Research Working Paper 5813.
7.
Conte, H. , R. Plutchik, K. Wild, and T. Karasu. 1986. Combined psychotherapy and pharmacotherapy for depression: A systematic analysis of the evidence. Archives of General Psychiatry43:471-479.
8.
Croghan, T. W. , C. Melfi, D. G. Dobrez, and T. J. Kniesner. 1999. Effect of mental health specialty care on antidepressant length of therapy. Medical Care37 (4): AS20-AS23.
9.
Croghan, T. , R. Obenchain, and W. Crown. 1998. What does treatment of depression really cost?Health Affairs17 (4): 198-208.
10.
Depression Guideline Panel . 1993. Depression in Primary care: Volume 2. Treatment of Major Depression. AHCPR Pub. No. 93-0551. Clinical Practice Guideline, Number 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health Services, Agency for Health Care Policy and Research.
11.
Finklestein, S. N. , E. R. Berndt, P. E. Greenberg, R. A. Parsley, J. M. Russell, and M. B. Keller. 1996. Improvement in subjective work performance after treatment of chronic depression: Some preliminary results. Psychopharmacology Bulletin32:34-40.
12.
Frank, R. G. , C. Koyanagi, and T. G. McGuire. 1997. The politics and economics of mental health “parity” laws. Health Affairs16 (4): 108-119.
13.
Freudenheim, M.1999. Decision on care back to doctors. The New York Times,9 November.
14.
Goldman, W. , J. McCulloch, B. Cuffel, D. A. Zarin, A. Suarez, and B. J. Burns. 1998. Outpatient utilization patterns of integrated and split psychotherapy and pharmacotherapy for depression. Psychiatric Services49:477-482.
15.
Goetzel, R. , D. Anderson, R. W. Witmer, R. J. Ozminkowski, R. L. Dunn, J. Wasserman, and the HERO Research Committee. 1998. Relationship between modifiable health risk and health care expenditure: HERO health risk and cost database. Journal of Occupational and Environmental Medicine40 (10): 843-854.
16.
Greenberg, P. , L. E. Stiglin, S. Finklestein, and E. R. Berndt. 1993. The economic burden of depression in 1990. Journal of Clinical Psychiatry54:405-418.
Heckman, J. J.1979. Sample selection bias as a specification error. Econometrica47:153-161.
19.
Heckman, J. J. , and J. Smith. 1995. Assessing the case for social experiments. Journal of Economic Perspectives9 (2): 85-110.
20.
Hirschfeld, R.M.A. , M. B. Keller, S. Panico, B. S. Arons, D. Barlow, F. Davidoff, J. Endicott, J. Fromm, M. Goldstein, J. Gorman, D. Guthrie, R. G. Marek, T. A. Maurer, R. Meyer, K. Philips, J. Ross, T. L. Schwenk, S. S. Sharfstein, M. E. Thase, and R. J. Wyatt. 1997. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. Journal of the American Medical Association277 (4): 333-340.
21.
Hylan, T. R. , W. E. Crown, L. Meneades, J. H. Heilegenstein, C. A. Melfi, T. W. Croghan, and D. P. Buesching. 1999. SSRI antidepressant use patterns in the naturalistic setting: A multivariate analysis. Medical Care37 (4): AS36-AS44.
22.
Jeffrey, N.1999. HMOs face questions over push for group therapy. The Wall Street Journal, 11 January.
23.
Katon, W. , and M. Von Korff. 1995. Collaborative management to achieve treatment guidelines. Journal of American Medical Association273:1026-1031.
24.
Keller, M. B.1990. Underrecognition and undertreatment by psychiatrists and other health care professionals. Archive of Internal Medicine150:946-948.
25.
Keller, M. B. , P. W. Lavori, C. E. Lewis, and G. L. Klerman. 1983. Predictors of relapse in major depressive disorder. Journal of American Medical Association250:3299-3304.
26.
Kessler, R. , K. McGonagle, S. Zhao, C. Nelson, M. Hughes, S. Eshlerman, H. Wittchen, and K. Kendler. 1994. Lifetime and twelve-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry51 (1): 8-19.
27.
Lu, M.1999. The productivity of mental health care: An instrumental variable approach. Journal of Mental Health Policy and Economics2:59-71.
28.
Maj, M. , F. Veltro, R. Pivossi, S. Lobrace, and L. Maglicano. 1992. Patterns of recurrence of illness after recovery of an episode major depression: A prospective study. American Journal of Psychiatry149:95.
29.
McGuire, T.1981. Financing psychotherapy: Costs, effects, and public policy. Cambridge, MA: Ballinger.
30.
McIntosh, M. W. , and D. B. Rubin. 1999. On estimating the causal effects of DNR orders. Medical Care37 (8): 722-726.
31.
Mechanic, D.1996. Key policy considerations for mental health in the managed care era. In Mental health, United States, edited by R. Wanderscheid and M. Sonnenschein. Rockville, MD: Center for Mental Health Services, U.S. Department of Health and Human Services, Public Health Services, Substance Abuse and Mental Health Services Administration.
32.
Melfi, C. A. , A. Chawla, T. W. Croghan, M. P. Hanna, S. Kennedy, and K. Sredl. 1998. Effect of adherence to guidelines for depression treatment on relapse and recurrence in a Medicaid population. Archives of General Psychiatry55:1128-1132.
33.
Mintz, J. , L. I. Mintz, M. J. Arruda, and S. S. Hwang. 1992. Treatments of depression and the functional capacity to work. Archives of General Psychiatry49:761-768.
34.
Pescosolido, B. , E. Wright, M. Alegria, and M. Vera. 1998. Social networks and patterns of use among the poor with mental health problems in Puerto Rico. Medical Care36 (7): 1057-1072.
35.
Polissar, L. , and P. Diehr. 1982. Regression analysis in health services research: The use of dummy variables. Medical Care20 (9): 959-966.
36.
Rice, T.1998. The economics of health reconsidered. Chicago: Health Administration Press.
37.
Rosenbaum, J. F. , M. Fava, S. L. Hoog, R. C. Ascroft, and W. B. Krebs. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry44 (2): 77-87.
38.
Rosenbaum, P. R. , and D. B. Rubin. 1984. Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association79:516-524.
39.
Rubin, D. B.1997. Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine127:757-763.
40.
Sturm, R. , and J. McCulloch. 1998. Mental health and substance abuse benefits in carve-out plans and the Mental Health Parity Act of 1996. Journal of Health Care Finance24 (3): 82-92.
41.
Sturm, R. , and K. B. Wells. 1995. How can care for depression be more cost-effective?Journal of American Medical Association273:51-58.
42.
Thompson, D. , D. Buesching, K. Gregor, and G. Oster. 1999. Patterns of antidepressant use and their relation to costs of care. American Journal of Managed Care2 (9): 1239-1246.
43.
Weissman, M. M. , B. A. Prusoff, A. DiMascio, C. Neu, M. Goklaney, and G. L. Klerman. 1979. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. American Journal of Psychiatry136:555-558.
44.
Wells, K. B. , R. Sturm, C. Sherbourne, and L. S. Meredith. 1996. Caring for depression. Cambridge, MA: Harvard University Press.
45.
Wilde, M. I. , and P. Benfield. 1998. Fluoxetine: Pharmacoeconomic review of its use in depression. Pharmacoeconomics13 (May): 543-561.
